

LFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<p>Re the application of:</p> <p>Lee, A. M. E. et al.</p> <p>Serial No: 10/693,316</p> <p>Filed: October 23, 2003</p> <p>For: <i>In Vitro Differentiation of Vascular Smooth Muscle Cells, Methods and Reagents Related Thereto</i></p>	<p>Group Art Unit: 1647</p> <p>Examiner: Not yet assigned</p> <p>Docket No.: HUV-046.02</p>
---	--

Certificate Of Mailing

I hereby certify that this "*Information Disclosure Statement*" is being deposited with the United States Postal Service with sufficient postage as First-Class Mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

January 26, 2005

Date of Mailing

Todd Williams

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of references AA – AY are not provided as they were previously cited by or submitted to the Patent Office in prior patent application no. 09/181,311 filed October 28, 1998, which is relied upon for an earlier filing date under 35 U.S.C. §120.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

- ☒ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**
- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- ☐ 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- ☐ 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Respectfully submitted,



Dana M. Gordon, Ph.D.
Attorney for Applicant(s)
Foley Hoag LLP
155 Seaport Boulevard
Boston, Massachusetts 02210-2600

Date: January 26, 2005
Reg. No. 44,719

Tel. No. (617) 832-1765
Fax No. (617) 832-7000

Form PTO-1449	Docket Number (Optional) HUV-046.02	Application Number 10/693,316
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		
Applicant Lee, A. M. E. et al.		Group Art Unit 1647
Filing Date 10/23/03		

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA 5,811,447	9/22/98	Kunz et al.	514	411	
	AB 5,773,479	1/30/98	Grainger et al.	514	651	
	AC 5,693,482	12/2/97	Anderson et al.	435	029	
	AD 5,589,376	12/31/96	Anderson et al.	435	240.2	
	AE 5,672,499	9/30/97	Anderson et al.	435	240.4	
	AF 5,654,183	8/5/97	Anderson et al.	435	172.3	
	AG 5,629,159	5/13/97	Anderson	435	006	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
	AH WO 97/23625	7/3/97	PCT				

OTHER DOCUMENTS*(Including Author, Title, Date, Pertinent Pages Etc.)*

AI	Hedin, U. et al., "Role of Tyrosine Kinases in Extracellular Matrix-Mediated Modulation of Arterial Smooth Muscle Cell Phenotype", Arteriosclerosis Thrombosis and Vascular Biology", 17:1977-1984 (1997).
AJ	Hsieh, C.-M., et al. "APEG-1, a Novel Gene Preferentially Expressed in Aortic Smooth Muscle Cells, Is Down-regulated by Vascular Injury", J. Bio. Chem., 271:17354-17359 (1996).
AK	Jain, M. et al., "In Vitro System for Differentiating Pluripotent Neural Crest Cells into Smooth Muscle Cells", J. Bio. Chem., 273:5993-5996 (1998).
AL	Kim, S. et al., "A Serum Response Factor-Dependent Transcriptional Regulatory Program Identifies Distinct Smooth Muscle Cell Sublineages", Moll. Cell. Biol., 17:2266-2278 (1997).
AM	Kirby, M. et al., "Neural Crest and Cardiovascular Patterning", Circulation Res., 77:211-215 (1995).
AN	Layne, M. et al., "Aortic Carboxypeptidase-like Protein, a Novel Protein with Discoidin and Carboxypeptidase-like Domains, Is Up-regulated during Vascular Smooth Muscle Cell Differentiation", J. Bio. Chem., 273:15654-15660 (1998).
AO	Lenkei, Z. et al., "Distribution of Angiotensin II Type-2 Receptor (AT) mRNA Expression in the Adult Rat Brain", J. Comparative Neurology, 373:322-339 (1996).
AP	Li, L. et al., "SM22 α , a Marker of Adult Smooth Muscle, Is Expressed in Multiple Myogenic Lineages During Embryogenesis", Circulation Research, 78:188-195 (1996).
AQ	Nackman, G. et al., "Endothelial cells modulate smooth muscle cell morphology by inhibition of transforming growth factor-beta1 activation", Surgery, 120:418-426 (1996).
AR	Rao, M. et al, "Immortalization and Controlled In Vitro Differentiation of Murine Multipotent Neural Crest Stem Cells", J. Neurobiology, 32:722-746 (1997).

Form PTO-1449		Docket Number (Optional) HUV-046.02	Application Number 10/693,316
INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>(Use several sheets if necessary)</i>		Applicant Lee, A. M. E. et al.	
		Filing Date 10/23/03	Group Art Unit 1647
	AS	Shah, N. et al., "Alternative Neural Crest Cell Fates Are Instructively Promoted by TGF β Superfamily Members", Cell, 85:331-343 (1996).	
	AT	Shanmugam, S. et al., "Otogeny of Angiotensin II Receptors", Cell Biology International, 20:169-176 (1996).	
	AU	Shanmugam, S. et al., "Otogeny of angiotensin II type 2 (AT2) receptor mRNA in the rat", Kidney International, 47:1095-1100 (1995).	
	AV	Sommer, L. et al., "The Cellular Function of MASH1 in Autonomic Neurogenesis", Neuron, 15:1245-1258 (1995).	
	AW	Status, R. et al., "Photodynamic therapy inhibits transforming growth factor β activity associated with vascular smooth muscle cell injury", J. Vascular Surg., 25:1044-1053 (1997).	
	AX	Stemple, D. et al., "Isolation of a Stem Cell for Neurons and Glia from the Mammalian Neural Crest", Cell, 71:973-985 (1992).	
	AY	Ward, Michael et al., "Inhibition of Protein Tyrosine Kinases Attenuates Increases in Expression of Transforming Growth Factor- β Isoforms and Their Receptors Following Arterial Injury", Arteriosclerosis, Thrombosis, and Vascular Biology, 17:2461-2470 (1997).	
EXAMINER			DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.			

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE